Sustainability to drive Pregis product development in Europe

Published: 10-Dec-2010
Packaging Finance

To focus on environmentally friendly products in 2011

The new president of Pregis’ European protective packaging business says the firm will focus on sustainable products in new product developments for 2011.

Kevin Baudhuin has been president of Pregis’ North American protective packaging business since 2007.

He has now been promoted to president of global protective packaging where he will lead Pregis Protective Packaging Europe.

Baudhuin said the firm aimed to create a broad environmentally friendly product portfolio suitable for a number of markets, including medical and pharmaceutical products.

The company already offers its Superlite poly Mailer and EP-Flex Renew biodegradable film products.

‘We recognise that any sustainable solution must still meet other key requirements such as high performance and cost-effectiveness and we will therefore ensure that our products continue to satisfy all these criteria,’ said Baudhuin.

He added that the firm’s growth strategy would focus on three main areas of sustainability, innovation and customer partnerships.

See more

You may also like

Manufacturing

Pregis announces film converting, equipment assembly facilities

Read more
The company’s converting equipment has been self-manufactured and was designed to ensure it’s capable of meeting performance goals including output, sealing and puncture resistance

Trending Articles

  1. MilliporeSigma to acquire JSR Life Sciences’ chromatography business, boosting Protein A purification capabilities The acquisition expands MilliporeSigma’s downstream bioprocessing portfolio with JSR’s Amsphere Protein A resin technology, enhancing efficiency and reliability in monoclonal antibody and therapeutic protein production
  2. Sharp appoints Samantha Wilson Jones as General Counsel Sharp Services has appointed Samantha Wilson Jones as General Counsel and Corporate Secretary of Sharp
  3. Sharp Services invests $100m to expand global sterile and packaging capacity across US and Europe The investment will boost sterile fill/finish, injectable packaging and oral solid dose capacity across Sharp's US and European sites, strengthening its clinical and commercial manufacturing network to meet growing pharmaceutical demand
  4. MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled

You may also like

Manufacturing

Pregis announces film converting, equipment assembly facilities

The company’s converting equipment has been self-manufactured and was designed to ensure it’s capable of meeting performance goals including output, sealing and puncture resistance
Packaging

Pregis launches high speed bagger with predictive maintenance

The unit features an intuitive user interface and thermal printing technology, which prints bar codes, graphics and alphanumeric fonts directly onto the package
Packaging

Pregis adds bagging systems to protective packaging portfolio

The protective packaging company has acquired Sharp Packaging Systems and its flexible bagging systems capability
Packaging

Pregis acquires UK-based protective packaging company Easypack

Will expand its North American portfolio to include paper void fill, cushioning and block/brace solutions
Finance

Shilpa Medicare opens flow chemistry manufacturing centre

The flow chemistry centre of excellence includes more than 100 R&D and manufacturing scientists
Manufacturing

OPTIMA machinery USA Corporation marks 40 years of growth and innovation in the US

OPTIMA machinery USA Corporation, a subsidiary of the German-based OPTIMA Packaging Group, is celebrating 40 years of successful operations in the United States
Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Subscribe now